Organon's Hormone-Free IUD Shows 6-Year Efficacy; FDA Review of Extended Use Underway
OGN has more than doubled off its 52-week low of $5.69.
Summary
Organon announced positive interim Phase 3 results for MIUDELLA, the hormone-free copper IUD it exclusively licensed from Sebela Women's Health in June 2026. Through 6 years of use, the cumulative Pearl Index was 0.93 and the Kaplan-Meier pregnancy rate was 3.9%, with bleeding- and pain-related discontinuations falling from 8.7% in year 1 to 1.9% in year 6. The FDA has accepted for review a supplemental NDA seeking to extend the label from 3 years to up to 6 years, with a PDUFA action expected in Q2 2027. This is a modest but real pipeline win for Organon's Women's Health franchise, though the company's near-term story remains dominated by the pending $14.00 per share acquisition by Sun Pharmaceutical, which shareholders approved in July. The data will be presented at the Society of Family Planning Annual Meeting on October 17, 2026. Watch the Q2 2027 PDUFA date for the extended-duration label decision.
At the time of this announcement, OGN was trading at $13.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.